Mastodon

Cefadroxyl Vatchem (Granules) Instructions for Use

Marketing Authorization Holder

Waltham-Pharmacy, LLC (Russia)

ATC Code

J01DB05 (Cefadroxil)

Active Substance

Cefadroxil (Rec.INN registered by WHO)

Dosage Form

Bottle Rx Icon Cefadroxil Vatchem Granules for the preparation of an oral suspension 250 mg/5 ml of the prepared susp.: bottle 45 g

Dosage Form, Packaging, and Composition

Granules for the preparation of an oral suspension white or white with a yellowish tint.

5 ml of the prepared susp.
Cefadroxil 250 mg

Excipients: saccharin, gum, magnesium stearate, colloidal silicon dioxide, titanium dioxide, peach and apricot flavor, talc, sucrose.

45 g – bottles (1) complete with a measuring spoon – cardboard packs.

Clinical-Pharmacological Group

First generation cephalosporin

Pharmacotherapeutic Group

Antibiotic-cephalosporin

Pharmacological Action

A first-generation broad-spectrum cephalosporin antibiotic for oral administration. It has a bactericidal effect.

It is active against gram-positive bacteria: Staphylococcus spp. (penicillinase-producing and non-producing strains), Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae, Bacillus anthracis; gram-negative bacteria: Shigella spp., Salmonella spp., Haemophilus influenzae, Escherichia coli, Klebsiella spp., some strains of Proteus spp.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to cefadroxil, including: diseases of the urinary tract, upper and lower respiratory tract, skin, soft tissues, bones.

ICD codes

ICD-10 code Indication
J00 Acute nasopharyngitis (common cold)
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J31.2 Chronic pharyngitis
J32 Chronic sinusitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
L01 Impetigo
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L08.0 Pyoderma
L08.8 Other specified local infections of skin and subcutaneous tissue
M00 Pyogenic arthritis
M86 Osteomyelitis
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30 Cystitis
N34 Urethritis and urethral syndrome
N41 Inflammatory diseases of prostate
N70 Salpingitis and oophoritis
N71 Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
N72 Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
T79.3 Posttraumatic wound infection, not elsewhere classified
ICD-11 code Indication
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0 Bullous impetigo
1B72.1 Nonbullous impetigo
1B72.Z Impetigo, unspecified
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
1B7Y Other specified pyogenic bacterial infections of skin or subcutaneous tissue
1C44 Non-pyogenic bacterial infections of skin
CA00 Acute nasopharyngitis
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA09.2 Chronic pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
EA50.3 Staphylococcal scarlet fever
EB21 Pyoderma gangrenosum
FA1Z Infectious arthropathies, unspecified
FB84.Z Osteomyelitis or osteitis, unspecified
GA01.Z Inflammatory diseases of uterus, except cervix, unspecified
GA07.Z Salpingitis and oophoritis, unspecified
GA91.Z Inflammatory and other diseases of prostate, unspecified
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
GC00.Z Cystitis, unspecified
GC02.Z Urethritis and urethral syndrome, unspecified
NF0A.3 Posttraumatic wound infection, not elsewhere classified
GA0Z Inflammatory diseases of female genital tract, unspecified
XA5WW1 Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

The dosage is set individually, taking into account the severity and localization of the infection, and the sensitivity of the pathogen. For oral administration in adults and children with a body weight over 40 kg, the average dose is 1-2 g/day in 1-2 doses. For children with a body weight less than 40 kg – 25-50 mg/kg/day (preferably in the form of a suspension) in 1-2 doses. The course of treatment is 7-14 days. The minimum duration of treatment for infectious and inflammatory diseases caused by group A beta-hemolytic streptococcus is 10 days.

For patients with impaired renal excretory function, the single dose is 500 mg, the intervals between doses are determined depending on the CC values: with CC 0-10 ml/min – 36 h; with CC 10-25 ml/min – 24 h; with CC 25-50 ml/min – 12 h.

Adverse Reactions

Allergic reactions are possible (urticaria, skin itching, eosinophilia; in isolated cases – angioedema, anaphylactic shock); rarely – nausea, vomiting, diarrhea, candidiasis, headache, dizziness; in some cases – changes in the peripheral blood picture (reversible leukopenia, neutropenia, thrombocytopenia).

Contraindications

Hypersensitivity to cephalosporins.

Use in Pregnancy and Lactation

Use during pregnancy and lactation (breastfeeding) is possible only in cases where the intended benefit to the mother outweighs the potential risk to the fetus or child.

Use in Renal Impairment

For patients with impaired renal excretory function, the single dose is 500 mg, the intervals between doses are determined depending on the CC values: with CC 0-10 ml/min – 36 h; with CC 10-25 ml/min – 24 h; with CC 25-50 ml/min – 12 h.

Pediatric Use

Use is possible according to the dosing regimen.

Special Precautions

In patients with hypersensitivity to penicillins, allergic reactions to cephalosporin antibiotics are possible.

Alcohol should not be consumed during treatment.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS